Fig 1: CXCR2 inhibition by AZD5069 diminishes doxorubicin chemoresistance in MDA-MB-231 mammospheres. (A) Cell cytotoxicity in control and treated conditions obtained from the LDH assay. Data are expressed as cytotoxicity percentage. Dox: doxorubicin; AZD: AZD5069. p values: The cytotoxicity of each combined treatment group was compared to the cytotoxicity of doxorubicin alone using unpaired Student’s t-test. ****p < 0.0001, ns = p = 0.2473. (B) Cell cytotoxicity in control and treated conditions obtained from the LDH assay. Data are expressed as cytotoxicity percentage. Dox: doxorubicin; AZD: AZD5069. p values. The cytotoxicity of each combined treatment group was compared to the cytotoxicity of the corresponding dose of AZD alone using unpaired Student’s t-test. ****p < 0.0001, **p = 0.002.
Fig 2: Targeting CXCR2 ultimately fosters sensitivity to anti-PDL1 immunotherapy in MDA-MB-231 cells cultured with PBMCs. (A) Cell cytotoxicity in control and treated conditions obtained from the LDH assay. Data are expressed as cytotoxicity percentage. Anti-PDL1: atezolizumab 200 nM; AZD: AZD5069. p values. The cytotoxicity of each combined treatment group was compared to the cytotoxicity of atezolizumab alone using unpaired Student’s t-test, ns = p = 0.0607. (B) Cell cytotoxicity in control and treated conditions obtained from the LDH assay. Data are expressed as cytotoxicity percentage. Anti-PDL1: atezolizumab 200 nM; AZD: AZD5069. p values. The cytotoxicity of each combined treatment group was compared to the cytotoxicity of atezolizumab alone using unpaired Student’s t-test, **p = 0.0065.
Supplier Page from MyBioSource.com for Lactate Dehydrogenase Assay Kit